Are there sales channels for Ensifentrine in the country?

Ohtuvayre (Ensifentrine)-Ensefentine Inhalation Suspension Solution has not yet received marketing approval from the State Food and Drug Administration in mainland China. Therefore, this drug cannot be purchased or reimbursed in regular pharmacies, hospitals, and medical insurance catalogs. As a new COPD treatment drug that has just been approved in the United States, its overseas trade name is Ohtuvayre. It is an inhalation suspension preparation and is suitable for the treatment of adult patients with chronic obstructive pulmonary disease (COPD) via nebulizer inhalation.

For domestic patients with COPD, if they have tried conventional bronchiectasis treatment but still have poor efficacy, and there are clear indications for medication, and there is a real clinical need, they may consider obtaining the US version of Ohtuvayre through overseas drug purchase channelsOhtuvayre. However, it needs to be made clear that overseas drugs are not official drugs approved for import by China’s State Food and Drug Administration, and cannot be reimbursed through medical insurance. The price is generally higher, the purchase cycle is longer, and there are certain risks in the storage and transportation of drugs.

Currently, some international medical service platforms or overseas medical institutions can assist domestic patients in obtaining U.S. original Ensefantine. Patients need to provide English prescriptions, identity documents, disease diagnosis reports and other materials. It is recommended to choose a platform with certification and good reputation to ensure that the source of drugs is formal and the transportation is legal. Do not buy through private purchasing or informal e-commerce platforms to prevent the purchase of fake or inferior drugs. In addition, you should ensure that you evaluate the risks and indications under the guidance of a professional doctor before deciding whether to start this type of overseas medication.

It is worth noting that many domestic pharmaceutical companies and scientific research institutions are paying close attention to the international research trends of exefantine, and are expected to introduce and carry out clinical trials or drug registration in the future. If it is successfully launched, it is expected to greatly improve its accessibility and affordability in the country, and is also expected to be gradually included in the medical insurance catalog to serve a wider group of COPD patients.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html